Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) Given Consensus Rating of “Buy” by Analysts

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $4.25.

A number of research firms have weighed in on ATNM. Zacks Investment Research downgraded Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 4th. Finally, William Blair began coverage on Actinium Pharmaceuticals in a report on Thursday, August 8th. They issued an “outperform” rating on the stock.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Sio Capital Management LLC increased its holdings in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 1,352.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,935,250 shares of the biotechnology company’s stock after purchasing an additional 4,595,454 shares during the quarter. Sio Capital Management LLC owned approximately 3.05% of Actinium Pharmaceuticals worth $1,214,000 at the end of the most recent reporting period.

Shares of NYSEAMERICAN:ATNM traded down $0.01 during midday trading on Thursday, reaching $0.21. 545,400 shares of the company’s stock traded hands, compared to its average volume of 1,092,915. Actinium Pharmaceuticals has a one year low of $0.20 and a one year high of $0.87.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: What is the definition of market timing?

Analyst Recommendations for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.